Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03410979 | A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects | PHASE1 | COMPLETED | 79 | — | — | Nov 25, 2016 | Aug 15, 2017 | Jan 25, 2018 | 1 | Netherlands |
To assess safety and tolerability of single and multiple ascending doses with GLPG2737 versus placebo in healthy subjects.
| Arm | Type | Description |
|---|---|---|
| GLPG2737 single dose | EXPERIMENTAL | Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order |
| Placebo single dose | PLACEBO_COMPARATOR | Single doses of Placebo oral suspension |
| GLP2737 multiple dose | EXPERIMENTAL | Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order |
| GLPG2737 multiple dose | PLACEBO_COMPARATOR | Multiple doses of Placebo oral suspension |
| Name | Type | Description |
|---|---|---|
| GLPG2737 single dose | DRUG | GLPG2737 oral suspension, single ascending doses |
| Placebo single dose | DRUG | Placebo, oral suspension. |
| GLPG2737 multiple dose | DRUG | GLPG2737 oral suspension, multiple ascending doses, daily for 14 days. |
Inclusion Criteria: 1. Male between 18-50 years of age, inclusive, on the date of signing the Informed Consent Form (ICF). 2. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical safety laboratory t...